Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03262389
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Overview
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.
Sponsor
Mayo Clinic
Phase
Phase 2
Contacts
Michael C Roarke (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT03262389Drug / Compound
Fludeoxyglucose
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Glucose Transport
Ligand Class: Small Molecules
Acetate
Isotope(s):
CARBON-11
Radioisotope: C-11
Theranostic Role: PET Imaging, SPECT Imaging
T1/2 (Half-Life): 20.4 Min
Decay Mode: POSITRON β+ (99.8%), ELECTRON CAPTURE (0.2%), GAMMA
Energy: max 0.96 MeV, mean 386 keV, Gamma 511 keV
Range: N/A
Decay Daughters: B11 (Stable)
Status: FDA Approval: Carbon 11 Choline (2012)
Target(s):
- Phospholipid Metabolism
Ligand Class: Small Molecules
Eligibility
Inclusion
- Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator
- English speaking
- Patients who have undergone standard of care workup
- 300 pounds or less
- Scheduled for a clinically indicated F-18 FDG PET scan
Exclusion
- Concurrent active non-multiple myeloma malignancy
- Previous Type I or Type II Diabetes mellitus or a fasting blood glucose \>150 mg/dl
- Pregnant, breast feeding
- Contraindication to PET MRI
Share your feedback
Help us improve your experience